Traumatic brain injury and Multiple Sclerosis are serious and often devastating clinical conditions being targeted by XOStem. Team research, including recently published data, equip us with the cell culturing, isolation, and delivery innovations needed to produce exosome based products that can improve and lengthen lives.
XOStem's first use of our Bio-Artificial organ is for Type-1 Diabetes with insulin-producing cells encased and protected by the biocompatible device. Other envisioned uses are delivery of therapeutic bio-compounds for a varety of diseases and medical conditions.
Joint rejuvenation and joint pain relief are areas where use of exosomes appears particularly promising. Development efforts are primarily focused on the knee. Reduction of inflammation, cartilage regrowth, tendon repair, and reduction or elimination of arthritis progression are sought after endpoints.
Skin rejuvenation and stimulating inactive hair follicles to once again sprout hair are active aesthetics targets. Our experience with products already in this market niche, in combination with purpose-specific engineered exosomes, will make existing products even more effective.
When companion dogs are diagnosed with type 1 diabetes, owners face a difficult decision. Daily long-term management with diet, blood glucose monitoring and insulin injections is effective yet requires dedicated owner involvement and substantial investment. Many owners opt for euthanasia. We offer another choice: an implantable bio-artificial pancreas that contains living insulin-producing cells that physiologically maintain normal glucose levels. We are in the final planning and regulatory stages to market such a device. Clinical experience and data from dogs will enable us to build our clinical evidence base for human trials.
Knee injuries in racehorses and camels result in euthanasia, if severe, or retirement from racing - unfortunate outcomes for the animal and owner. XOStem engineered exosomes will undergo testing as a methodology of repair and rejuvenation in racehorses and camels. Clinical evidence will help build the database necessary to transition this therapy into human clinical trials.